PRECOS and Janssen sign service agreement
Will support development of cancer drugs
Preclinical Oncology Services (PRECOS), a pre-clinical research and development service provider focused on oncology, has signed a service agreement with global pharmaceutical company Janssen Pharmaceutica.
The contract will see the UK firm provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.
PRECOS was launched as a spin-off from the University of Nottingham, UK in August. The service agreement is a consolidation of the working relationship between the two companies, which was first established with the University of Nottingham more than five years ago.
The company offers patient-relevant models for each aspect of cancer progression encompassing pre-cancerous lesions, primary tumours and metastasis.
Professor Sue Watson, chief scientific officer of PRECOS, said: ‘This global contract further strengthens the long-term relationship between PRECOS and Janssen and consolidates PRECOS’ evolution from a primarily academic background into an ambitious commercial entity, offering significant scientific expertise and delivering highly specialist services in the development of new anti-cancer drugs.’
